Together We Discover

Reaching Patients Through

Immunology Innovation

"GO" Decision: ADHERE Trial in CIDP

FEBRUARY 2021

1

Forward Looking Statements

This presentation has been prepared by argenx se ("argenx" or the "company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should

be construed as, a recommendation, promise or representation by the presenter or the company or any director, employee, agent, or adviser of the company. This presentation does not purport to

!

be all-inclusive or to contain all of the information you may desire. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size

and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to suchestimates.

Safe Harbor: Certain statements contained in this presentation, other than present and historical facts and conditions independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward-looking state- ments include those regarding our business and financial outlook and related plans; the therapeutic and commercial potential of our product candidates; the intended results of our strategy; the expected benefits of our collaborations, including with respect to our collaboration with Zai Lab; our and our collaboration partners' clinical development and regulatory plans, including the timing, design and outcome of ongoing and planned clinical trials and preclinical activities and the timing and outcome of regulatory filings and approvals; the timing, progress and benefits of marketing and commercialization activities; and the expected size of the markets for our product candidates. When used in this presenta- tion, the words "anticipate," "believe," "can," "could," "estimate," "expect," "intend,"

"is designed to," "may," "might," "will," "plan," "potential," "predict," "objective," "should," or the negative

of these and similar expressions identify forward-lookingstatements.

Such statements, based as they are on the current analysis and expectations of ma- nagement, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Company's control. Such risks include, but are not limited to: the impact of COVID-19 pandemic on our business, the impact of general economic conditions, general conditions in the biopharmaceutical industries, changes in the global and regional regulatory environments in the jurisdictions in which the Company does or plans to do business, market volatility, fluctuations in costsand

changes to the competitive environment. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. In the case of forward-looking statements regarding investigational product candidates and continuing further development efforts, specific risks which could cause actual results to differ materially from the Company's current analysis and expectations include: failure to demonstrate the safety, tolerability and efficacy of our product candidates; final and quality controlled verification of data and the related analyses; the expense and uncertainty of obtaining regulatory approval, including from the U.S. Food and Drug Administration and European Medicines Agency; the possibility of having to conduct additional clinical trials; our ability to obtain and maintain intellectual property protection for our product candidates; and our reliance on third parties such as our licensors and collaboration partners regarding our suite of technologies and product candidates. Further, even if regulatory approval is obtained, biopharmaceutical products are generally subject to stringent on-going govern- mental regulation, challenges in gaining market acceptance and competition. These statements are also subject to a number of material risks and uncertainties that are described in the Company's filings with the U.S. Securities and Exchange Commission ("SEC"), including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. The reader should not place undue reliance on any forward-looking statements included in this presentation. These statements speak only as of the date made and the Company is under no obligation and disavows any obligation to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation.

2

Efgartigimod: Broad Pipeline Opportunity

Landscape of

IgG-mediated Severe

Autoimmune Diseases

(sampling)

Immune Lupus Thrombocytopenia

Guillain-Barré syndrome

Myasthenia Gravis

Scleroderma

Anca Vasculitis

Solid Biology

Feasible for

Rationale:

Biotech:

Predominantly

Orphan indication,

mediated by

efficient clinical &

pathogenic IgGs

regulatory pathway

argenx Franchises & Indications

Efgartigimod to date achieved proof-of-concept in 4/4 indications; 2/2 in neuromuscular franchise

Myasthenia Gravis

Neuromuscular

Diseases

Chronic Inflammatory Demyelinating Polyneuropathy

5th indication

Hematology

Epidermolysis Bullosa

Acquisita

Neuromyelitis

Pemphigus Optica

Disorders

Immune Thrombocytopenia

Skin Blistering

Diseases

Pemphigus Vulgaris

Multiple Sclerosis

Membraneous Hemolytic Anemia

Nephropathy

Rheumatoid

Arthritis

Thyroid Eye Disease

Kidney

TBD

Bullous Pemphigoid

6th indication

3

CIDP: Significant Unmet Need Exists for Patients

Rare, Chronic, and

Progressive

Symmetric proximal and distal weakness with sensory loss and decreased reflexes

Can progress quickly to severe disability (wheelchair)

50% of patients are severely disabled at some stage of illness

Pain and fatigue commonly reported

Prevalence &

Opportunity

~16,000 patients in the US

> $ 3Bn in IVIG Sales globally

Diagnosis/Metrics

Commonly misdiagnosed

Diagnosis often confirmed by physicians trying therapy for 3 months and reassessing

Treatment

70% of CIDP patients need ongoing treatment

Available treatments come with long infusion times and adverse effects

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

arGEN-X SE published this content on 01 February 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 February 2021 07:39:02 UTC.